Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil

Inclusion Criteria: * Sign the ICF by the subject or the subject's legally acceptable representative; * Sign the ICF by the participant's family member; * Proven vaccination with one of the vaccines for COVID-19 available by the PNI, containing information on the date of application, type (manufacturer) of vaccine received and batch (desirable); * Meet the minimum criteria for a level of certainty 3, 2 or 1 in Brighton Collaboration for vaccine-induced immune thrombotic thrombocytopenia as described in 3.2.1.1 OR, * Meet the minimum criteria for a level of certainty 3, 2 or 1 in Brighton Collaboration for Guillain-Barré syndrome as described in 3.2.1.3 OR, * Meet the minimum criteria for a level of certainty 3, 2 or 1 in Brighton Collaboration for Acute Disseminated Encephalomyelitis as described in 3.2.1.4 OR, * Meet the minimum criteria for a level of certainty 3, 2 or 1 in Brighton Collaboration for Transverse Myelitis as described in 3.2.1.5 OR, * Be classified in the causality categories adopted by the PNI/MS, namely: A1, B1 or B2. Exclusion Criteria: * Reports in which it is not possible to retrieve the clinical/laboratory data necessary for evaluation, due to inadequate filling of the notification or unavailability of data; * Cases of death in which there are no samples available and/or suitable for carrying out the analyzes defined in the protocol; * Cases in which another diagnosis is made for the adverse event of interest, being discarded as a SAE; * Cases classified in causality categories (PNI/MS) as A2, A3, A4, C or D; * Refusal to sign the informed consent form;